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AbstrACt
Objective To summarise the incidental findings detected on 
brain imaging and blood tests during the first wave of data 
collection for the Insight 46 study.
Design Prospective observational sub-study of a birth 
cohort.
setting Single-day assessment at a research centre in 
London, UK.
Participants 502 individuals were recruited from the MRC 
National Survey of Health and Development (NSHD), the 1946 
British birth cohort, based on pre-specified eligibility criteria; 
mean age was 70.7 (SD: 0.7) and 49% were female.
Outcome measures Data regarding the number and types 
of incidental findings were summarised as counts and 
percentages, and 95% confidence intervals were calculated.
results 93.8% of participants completed a brain scan 
(n=471); 4.5% of scanned participants had a pre-defined 
reportable abnormality on brain MRI (n=21); suspected 
vascular malformations and suspected intracranial mass 
lesions were present in 1.9% (n=9) and 1.5% (n=7) 
respectively; suspected cerebral aneurysms were the 
single most common vascular abnormality, affecting 1.1% 
of participants (n=5), and suspected meningiomas were 
the most common intracranial lesion, affecting 0.6% of 
participants (n=3); 34.6% of participants had at least one 
abnormality on clinical blood tests (n=169), but few reached 
the prespecified threshold for urgent action (n=11).
Conclusions In older adults, aged 69-71 years, potentially 
serious brain MRI findings were detected in around 5% 
of participants, and clinical blood test abnormalities were 
present in around one third of participants. Knowledge of 
the expected prevalence of incidental findings in the general 
population at this age is useful in both research and clinical 
settings.
IntrODuCtIOn
Incidental clinical findings are often discov-
ered during the course of conducting research. 
An incidental finding can be defined as ‘a 
finding concerning an individual research 
participant that has potential health or repro-
ductive importance…but is beyond the aims of 
the study’.1 The primary aim of most research 
is to generate data and advance knowledge, 
rather than to diagnose health problems in 
participants, and there is currently no legal 
requirement for researchers in the UK to 
report incidental findings to participants.2 
There are, however, important ethical reasons 
for disclosing certain incidental findings to 
participants in appropriate circumstances, 
particularly when they relate to serious and 
potentially treatable conditions.1 It is there-
fore important that studies have protocols in 
place for managing them. While there is no 
consensus on how this should be done, it is 
recommended that researchers weigh up the 
potential benefits and harm to participants of 
being informed, as well as considering the asso-
ciated time and cost, both to the study and to 
publicly funded health services.2 
strengths and limitations of this study
 ► A large number of participants underwent brain im-
aging and blood testing, at an almost identical age, 
and received feedback of incidental findings accord-
ing to a prespecified standardised protocol.
 ► Participants were recruited from the 1946 British 
birth cohort, a broadly representative sample of 
the  population born in mainland Britain during 
one week in 1946.
 ► Participant perception regarding the disclosure of 
incidental findings was not formally assessed, nor 
was the impact on their longer term health and psy-
chological well-being.
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Incidental findings often lead to anxiety and have the 
potential to lead to unnecessary and invasive procedures 
for study participants.3–5 Knowledge of the expected prev-
alence of incidental findings, based on clearly defined 
protocols for their determination, is important, allowing 
researchers to be better prepared for managing them and 
enabling study participants to be appropriately informed 
as part of the consent process. Given the increasing use 
of neuroimaging in primary, secondary and tertiary care, 
such information is also useful in the clinical setting, 
where it can facilitate management decisions. For 
example, knowing the probability of detecting an abnor-
mality unrelated to a patient’s symptoms might influence 
a clinician’s decision to recommend a brain scan in a 
patient presenting with a benign-sounding headache, or 
prompt discussion with the patient regarding the pros 
and cons of scanning.
The MRC National Survey of Health and Development 
(NSHD) recruited 5362 individuals born in England, 
Scotland and Wales during the same week in 1946, and 
has followed them since birth, with over 2500 participants 
remaining in active follow-up.6 Insight 46 is a longitu-
dinal neuroimaging substudy of 502 NSHD participants, 
which aims to investigate genetic and life course factors 
that contribute to healthy and pathological brain ageing, 
in particular cerebrovascular and Alzheimer’s disease. It 
involves detailed clinical phenotyping, brain magnetic 
resonance imaging (MRI), cerebral ß-amyloid positron 
emission tomography (PET), and blood and urine collec-
tion, at two time points approximately two years apart. 
The full study protocol, which includes clear criteria 
for reporting incidental findings, has been described 
elsewhere.7
The aim of this study is to summarise the incidental 
findings detected on brain MRI and blood tests during the 
first wave of data collection for Insight 46. Several studies 
have reported rates of incidental findings in different 
samples previously,8 9 but to our knowledge none have 
reported on findings from a representative country-wide 
birth cohort.
MethODs
recruitment
Individuals were recruited from NSHD participants who 
attended a study visit at age 60–64, who had previously indi-
cated that they would be willing to consider participating in 
a study visit in London, and for whom relevant life course 
data were available (online supplementary file 1). NSHD 
participants who met these criteria were sent an informa-
tion booklet about the study and then recruited by a study 
doctor via telephone. Those with known contraindications 
to PET or MRI scanning were not recruited. Eligibility 
criteria were relaxed towards the end of the study, allowing 
inclusion of some individuals with a few missing life course 
data points, in order to achieve the study’s recruitment 
target.
Consent
The booklet sent to participants prior to their visit contained 
a detailed description of the study tests, including infor-
mation about the study protocol with regard to incidental 
findings. Specifically, it stated that ‘we will inform you and 
your GP if any of the routine blood tests show any signif-
icant abnormalities’ and we ‘will let you and your doctor 
know if there are any major abnormalities on the MRI 
scan (eg, the presence of a tumour or a large aneurysm) 
which might affect your clinical care’. It also emphasised 
that ‘being in a research study does not take the place of 
routine physical examinations or other appointments with 
your doctor and should not be relied upon to diagnose or 
treat medical problems’. All participants provided written 
consent to participate (online supplementary file 2). Prior 
to collecting blood samples, the study doctor asked partic-
ipants whether they wished to opt out of receiving a copy 
of their blood results. This option was given primarily to 
avoid overwhelming participants with feedback, with a view 
to contacting these participants only if they had actionable 
findings. They had to consent to their general practitioner 
(GP) being informed about them.
neuroimaging
Participants underwent brain imaging on a single Biograph 
mMR 3 Tesla PET/MRI scanner (Siemens Healthcare). 
Participants were injected via an intravenous cannula with 
the 18F amyloid PET ligand florbetapir at the start of the 
imaging session, and dynamic amyloid data were obtained 
over 60 min. MRI data were acquired simultaneously, 
including volumetric T1-weighted, T2-weighted and 
fluid-attenuated inversion recovery (FLAIR) sequences; 
resting-state functional MRI; multishell diffusion-weighted 
imaging; three-dimensional gradient echo sequence for 
T2*-weighted/susceptibility weighted imaging; and arterial 
spin labelling (non-invasive perfusion imaging).
blood tests
Participants provided blood samples for standard clinical 
tests including haemoglobin, platelet count, vitamin B12, 
urea, creatinine, random glucose and thyroid stimulating 
hormone (TSH). Samples were also taken for biomarker 
and genetic testing. Results of the clinical blood tests were 
reported back to the study team via email within 24 hours. 
Samples for biomarker and genetic testing were stored for 
future analysis.
Duty of care protocol for neuroimaging
Given that Insight 46 participants were scanned at a single 
centre with availability of consultant neuroradiologists, and 
due to the unique nature of the cohort, it was decided that 
MRI scans would have a radiologist review. All T1-weighted, 
T2-weighted and FLAIR MRI sequences were reviewed by 
one of two consultant neuroradiologists within two weeks of 
the scan. Other sequences were not routinely reviewed on 
the basis that they do not form part of a standard diagnostic 
MRI examination in clinical practice. Neuroradiologists 
used a list of prespecified reportable and non-reportable 
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abnormalities to flag scans as being potentially reportable 
(table 1). This list was adapted from the UK Biobank study, 
which classified findings as reportable if they were poten-
tially serious (i.e. life-threatening or likely to have a major 
impact on quality of life or function), based primarily on 
work performed by the German National Cohort.5 10 Aneu-
rysms <7 mm were not considered reportable in keeping 
with the Rotterdam Scan Study.11 Neuroradiologists were 
also encouraged to flag scans with other unexpected find-
ings if there was any possibility that further assessment 
might be required.
The reporting process was performed electronically using 
the web-based data management tool XNAT ( www. xnat. 
org), thereby providing an audit trail (figure 1). Reporting 
radiologists downloaded images from the XNAT server, 
reviewed them and then completed a radiological read 
report within XNAT (online supplementary file 3). This 
took around ten minutes per scan. Radiologists were not 
given any clinical information regarding participants, other 
than knowing that they were all born in 1946. If a scan was 
flagged as potentially reportable, the study coordinator was 
automatically notified, and a multidisciplinary meeting was 
organised within four weeks of the study visit. The reporting 
neuroradiologist, study chief investigator and other relevant 
members from the study team were present at this meeting. 
If the abnormality was agreed to meet the criteria for being 
reportable, the team decided on a clinical action plan (eg, 
further imaging and/or specialist referral). A study doctor 
then contacted the participant and their GP, by telephone 
and in writing, providing them with information about the 
MRI abnormality and the recommended clinical action. 
Since data were collected in an anonymised form, it was not 
possible to share the images for clinical use.
Results of the amyloid PET scan were not fed back to 
participants because of the diagnostic and prognostic 
uncertainties of using this test in cognitively normal indi-
viduals and lack of disease-modifying treatments for people 
with amyloid pathology. These ethical considerations have 
been discussed elsewhere.12
Duty of care protocol for blood tests
Results of the clinical blood tests were reviewed by the study 
doctor and reported back to the participant’s GP in writing 
within two weeks of the study visit. The participant was also 
sent a copy of these results if they had previously stated that 
they wished to receive one. If results fell outside the normal 
reference range (table 2), these abnormalities were high-
lighted in a letter sent to both the participant and their GP, 
and participants were advised to discuss them with their GP. 
If results were deemed to be significantly abnormal, falling 
beyond prespecified urgent action levels (table 2), the 
study doctor contacted the participant and their GP by tele-
phone within 48 hours of the study visit. These prespecified 
levels were adapted from those used at the NSHD whole 
cohort sweep at age 60–64.6 They reflect values at which 
urgent action would be warranted in clinical practice and 
were developed in consultation with clinical scientists and 
physicians in the relevant field. Biomarker and genetic test 
results were not reported back to participants.
Follow-up of incidental findings on brain MrI
While participants have not been systematically followed up 
with regard to findings detected on brain MRI, data 
regarding outcomes have been obtained via different 
sources, mainly through telephone or written communi-
cation from participants, or through letters obtained from 
healthcare professionals.
Table 1 List of reportable and non-reportable MRI abnormalities (adapted from the UK Biobank, German National Cohort and 
Rotterdam Scan studies)5 10 11
Reportable findings Non-reportable findings
 ► Acute brain infarction.
 ► Acute brain haemorrhage (note: not old bleeds).
 ► Intracranial mass lesions (note: not meningiomas in locations considered 
unlikely to cause problems).
 ► Suspected intracranial aneurysm or vascular malformation (including 
cavernomata) (note: not aneurysms <7 mm in diameter).
 ► Colloid cyst of the third ventricle.
 ► Acute hydrocephalus.
 ► Significant sinus disease with suspicion of underlying pathology (eg, 
unilateral sinus opacification).
 ► Other unexpected, serious or life-threatening findings.
 ► White matter hyperintensities.
 ► Suspected demyelination.
 ► Non-acute brain infarction.
 ► Chronic hydrocephalus.
 ► Asymmetric ventricles.
 ► Lipoma of the corpus callosum.
 ► Developmental abnormalities.
 ► Enlarged perivascular spaces.
 ► Chiari malformation.
 ► Hippocampal or other focal atrophy.
Figure 1 Simplified overview of the process for viewing and 
reporting scans using XNAT. QC, quality control; PETMR, 
positron emission tomography and magnetic resonance
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Analysis
Data regarding the number and types of incidental find-
ings, and the actions taken by the study team in response 
to them, were summarised as counts and percentages, and 
95% CIs for proportions were calculated using the exact 
Clopper-Pearson method. Sex differences were assessed 
using a two-tailed two-sample test of proportions. A p value 
<0.05 was considered significant. For brain MRI analyses, 
participants without a scan were excluded. For blood 
result analyses, participants were excluded if they had a 
missing value for the specific test or category being anal-
ysed. Very few participants had missing blood result values, 
primarily due to sampling or processing errors, and these 
were assumed to have occurred at random. All analyses 
were performed in STATA V.14.2. Estimated glomerular 
filtration rate (eGFR) was derived using the Modifica-
tion of Diet in Renal Disease study equation: GFR (mL/
min/1.73 m2)=175 × (Scr/88.4)−1.154 × (age)−0.203 (× 0.742 if 
female), where Scr is serum creatinine in µmol/L.
Participant involvement
Study members helped in the design of the Insight 46 study 
through participation in focus groups. Participants were 
invited to complete evaluation forms following their study 
visit, outlining any positive or negative aspects of their expe-
rience. Results from the Insight 46 study will be dissemi-
nated to participants through newsletters and public 
engagement events.
results
502 participants attended a study visit in London from 
throughout mainland Britain between May 2015 and 
January 2018. The mean age was 70.7 (SD: 0.7) years and 
49% were female. In total, 181 participants had a report-
able incidental finding on either brain MRI or clinical 
blood tests, and 45 participants had more than one report-
able finding.
brain MrI
93.8% of participants completed a brain scan (n=471). 
The most common reason for non-completion was claus-
trophobia (n=25). Other reasons included: being unable 
to lie comfortably in the scanner (n=3); concerns about 
radiation (n=1); possible metallic implants (n=1); and with-
drawal from the study (n=1). 7.6% of scans (n=36) were 
flagged by neuroradiologists as having potentially report-
able abnormalities for review. Following discussion between 
the reporting neuroradiologist and study chief investigator, 
58.3% of these scans (n=21) were deemed to have an abnor-
mality that fulfilled the criteria for being reportable. There-
fore, in total, 4.5% of all scans had an incidental finding 
that was reported to the participant and their GP. Details of 
flagged findings that were not deemed reportable are listed 
in online supplementary file 4.
Table 3 Number and percentage of reportable MRI abnormalities by type and sex
All (N=471) Male (N=241) Female (N=230)
n % (95% CI) n % (95% CI) n % (95% CI)
Any abnormality 21 4.5 (2.8 to 6.7) 6 2.5 (0.9 to 5.3) 15 6.5 (3.7 to 10.5)
Acute brain infarction – – – – – – 
Acute brain haemorrhage – – – – – – 
Suspected intracranial mass lesion 7 1.5 (0.6 to 3.0) 2 0.8 (0.1 to 3.0) 5 2.2 (0.7 to 5.0)
Suspected intracranial aneurysm or vascular 
malformation
9 1.9 (0.9 to 3.6) 2 0.8 (0.1 to 3.0) 7 3.0 (1.2 to 6.2)
Colloid cyst of the third ventricle – – – – – – 
Acute hydrocephalus – – – – – – 
Significant sinus pathology 3 0.6 (0.1 to 1.9) 1 0.4 (0.0 to 2.3) 2 0.9 (0.1 to 3.1)
Other* 2 0.4 (0.0 to 1.5) 1 0.4 (0.0 to 2.3) 1 0.4 (0.0 to 2.4)
*Possible keratocystic odontogenic tumour of the right mandible (n=1); hyperintense area in the suprasellar cistern with differential diagnosis 
of small dermoid cyst, craniopharyngioma or thrombosed anterior communicating artery aneurysm (n=1).
Table 2 Clinical blood tests, their normal reference ranges 
and urgent action levels
Blood test
Normal 
reference range
Urgent action 
level
Haemoglobin 
(male), g/L
130–170 <100 or >200 
Haemoglobin 
(female), g/L
115–155 <100 or >200 
Platelets, ×109/L 150–400 <100 or >1000 
Vitamin B12, pg/mL 191–900 <100
Urea, mmol/L 1.7–8.3 >20
Creatinine 
(male), μmol/L
66–112 >200
Creatinine 
(female), μmol/L
49–92 >200
Glucose, mmol/L 3.5–10 >20
Thyroid stimulating 
hormone, mIU/L
0.27–5.5 <0.1 or >10
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Table 3 summarises the number and percentage of 
reportable MRI abnormalities by type and sex. The most 
common abnormalities were suspected vascular malforma-
tions and suspected intracranial mass lesions, which were 
detected in 1.9% (n=9) and 1.5% (n=7) of participants 
respectively. Suspected cerebral aneurysms were the most 
common vascular abnormality, affecting 1.1% of partici-
pants (n=5; figure 2A). Suspected meningiomas were the 
most common intracranial lesion, affecting 0.6% of partic-
ipants (n=3; figure 2B). Women were more likely to have 
a reportable MRI abnormality than men (6.5% vs 2.5%; 
p=0.034).
With regard to management of incidental findings, 
further imaging was recommended in 66.6% of cases 
(n=14); specialist referral was advised in 57.1% of cases 
(n=12); advice regarding medication and management 
was given in 19% of cases (n=4); and no action was recom-
mended in 9.5% of cases where the abnormalities were 
found to be pre-existing and already being managed by 
the participant’s local health services (n=2). Further infor-
mation regarding follow-up and subsequent outcomes is 
summarised in online supplementary file 5.
standard clinical blood tests
Venepuncture was successful in over 99% of participants 
(n=498). Almost all participants chose to receive a copy 
of their clinical blood test results (n=496). There were 
missing blood result values in some participants (n=9) due 
to insufficient samples, lab errors, clumped platelets or a 
clotted sample. Of participants with complete blood result 
data, 34.6% had at least one abnormality on standard clin-
ical blood tests (n=169). Of those participants with abnor-
malities, urgent action was required for 6.5% (n=11). In 
many of these cases (n=6), the participant’s GP confirmed 
that the abnormality was pre-existing and already being 
managed. Table 4 summarises the number and percentage 
of blood test abnormalities by type and sex. Overall, men 
were significantly more likely to have at least one blood 
test abnormality than women (40.8% vs 28.0%; p=0.003). 
However, removing ‘low creatinine’ as an abnormality 
resulted in there being no significant difference between 
men and women (30.8% vs 26.4%; p=0.277).
Figure 2 (A) Sagittal T1-weighted image demonstrating a 
10 mm aneurysm (arrow) arising from the tip of the basilar 
artery. (B) Coronal FLAIR image demonstrating a broad-
based, extra-axial lesion (asterisk) overlying the right superior 
frontal gyrus, consistent with a meningioma. FLAIR, fluid-
attenuated inversion recovery.
Table 4 Number and percentage of clinical blood test abnormalities by type and sex
All (N=498) Male (N=255) Female (N=243)
n/N % (95% CI) n/N % (95% CI) n/N % (95% CI)
Any abnormality 169/489 34.6 (30.3 to 39.0) 102/250 40.8 (34.6 to 47.2) 67/239 28.0 (22.4 to 34.2)
Polycythaemia 15/494 3.0 (1.7 to 5.0) 11/254 4.3 (2.2 to 7.6) 4/240 1.7 (0.5 to 4.2)
Anaemia 19/494 3.8 (2.3 to 5.9) 14/254 5.5 (3.0 to 9.1) 5/240 2.1 (0.7 to 4.8)
Thrombocytosis 10/492 2.0 (1.0 to 3.7) 2/252 0.8 (0.1 to 2.8) 8/240 3.3 (1.4 to 6.5)
Thrombocytopaenia 11/492 2.2 (1.1 to 4.0) 9/252 3.6 (1.6 to 6.7) 2/240 0.8 (0.1 to 3.0)
Elevated vitamin B12 10/495 2.0 (1.0 to 3.7) 5/253 2.0 (0.6 to 4.6) 5/242 2.1 (0.7 to 4.8)
Low vitamin B12 16/495 3.2 (1.9 to 5.2) 6/253 2.4 (0.9 to 5.1) 10/242 4.1 (2.0 to 7.5)
Elevated urea 40/497 8.0 (5.8 to 10.8) 23/254 9.1 (5.8 to 13.3) 17/243 7.0 (4.1 to 11.0)
Elevated creatinine 17/497 3.4 (2.0 to 5.4) 10/254 3.9 (1.9 to 7.1) 7/243 2.9 (1.2 to 5.8)
Low creatinine 41/497 8.2 (6.0 to 11.0) 33/254 13.0 (9.1 to 17.7) 8/243 3.3 (1.4 to 6.4)
eGFR <60* 43/497 8.7 (6.3 to 11.5) 15/254 5.9 (3.3 to 9.6) 28/243 11.5 (7.8 to 16.2)
Hyperglycaemia 21/497 4.2 (2.6 to 6.4) 16/254 6.3 (3.6 to 10.0) 5/243 2.1 (0.7 to 4.7)
Hypoglycaemia 5/497 1.0 (0.3 to 2.3) 1/254 0.4 (0.0 to 2.2) 4/243 1.6 (0.5 to 4.2)
Elevated TSH 13/496 2.6 (1.4 to 4.4) 4/253 1.6 (0.4 to 4.0) 9/243 3.7 (1.7 to 6.9)
Low TSH 9/496 1.8 (0.8 to 3.4) – – 9/243 3.7 (1.7 to 6.9)
Urgent action 11/489 2.2 (1.1 to 4.0) 3/250 1.2 (0.2 to 3.5) 8/239 3.3 (1.5 to 6.5)
NB, Participants were excluded if they had a missing value for the specific test or category being analysed.
*eGFR (mL/min/1.73 m2) was calculated to facilitate comparison with other studies; it was not reported back to participants.
eGFR, estimated glomerular filtration rate; TSH, thyroid stimulating hormone. 
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DIsCussIOn
In this study of older adults, aged 69–71, reportable inci-
dental findings on brain MRI were present in 4.5% of 
scanned participants, with suspected vascular malfor-
mations and suspected intracranial mass lesions present 
in 1.9% and 1.5% of participants respectively. Clinical 
blood test abnormalities were common, affecting around 
one-third of participants. However, very few blood test 
abnormalities required urgent action, and many of those 
that did were previously known to the participants’ GPs and 
had already been acted on.
Comparison with other studies
Due to the recent proliferation of neuroimaging research, 
incidental findings on brain MRI are often reported in 
the literature.8 9 The reported prevalence varies between 
studies, likely reflecting differences in the definition of 
what constitutes an incidental finding, as well as variability 
in participant demographics and imaging protocols. Many 
imaging studies do not require routine review of all scans 
by a radiologist, and researchers will only ask for a radiol-
ogist opinion if an abnormality is identified incidentally by 
a radiographer during scanning or by researchers during 
data analysis.13 14 Such studies may have lower detection 
rates, but are presumably less likely to publish data on inci-
dental finding prevalence.
A 2018 systematic review reported an overall prevalence 
of 1.4% (95% CI 1.0% to 2.1%) for potentially serious 
brain incidental findings.8 This is somewhat lower than the 
4.5% (95% CI 2.8% to 6.7%) detected in Insight 46 partici-
pants, although this review consisted mainly of studies with 
younger participants using MRI scanners of 1.5 Tesla or less. 
Most of the studies in this review used at least one radio-
logical reader. Another systematic review reported a much 
higher prevalence of 22% (95% CI 14% to 31%), likely due 
to their inclusion of all findings, regardless of their clinical 
seriousness.9 Comparing specific abnormalities, namely 
suspected intracranial mass lesions and vascular malforma-
tions, in Insight 46 and 1936 Lothian Birth Cohort (LBC) 
revealed similar rates: 1.4% (95% CI 0.7% to 2.6%) and 
2% (95% CI 1.1% to 3.3%) respectively in LBC subjects 
aged 73, compared with 1.5% (95% CI 0.6% to 3.0%) and 
1.9% (95% CI 0.9% to 3.6%) in Insight 46.15 Results from 
another large population-based study, which included over 
5800 subjects with a mean age 64.9 years, were marginally 
higher than Insight 46, with a prevalence of 2.5% (95% CI 
2.1% to 2.9%) for suspected meningiomas and 2.3% (95% 
CI 2.0% to 2.7%) for suspected cerebral aneurysms.11
Most previous studies have found no significant difference 
in prevalence of potentially serious brain MRI findings by 
sex.8 In Insight 46, however, higher rates were observed in 
female versus male participants. This was primarily driven 
by greater numbers of suspected intracranial mass lesions 
and vascular abnormalities in women, possibly due to the 
fact that meningiomas and cerebral aneurysms are more 
common in women than in men.11
With regard to blood tests, Insight 46 tended to have 
either similar or lower rates of abnormalities than other 
studies. The prevalence of anaemia in a systematic review 
of studies involving community-dwelling older adults 
was 12%, which is somewhat higher than the 3.8% (95% 
CI 2.3% to 5.9%) detected in Insight 46 participants.16 
The prevalence of chronic kidney disease stages 3–5 
(eGFR <60 mL/min/1.73 m2) is estimated to be around 
6.1% in adults under 65 in England, rising to 13.5% 
for individuals aged 65–74, according to data collected 
in the 2009–2010 Health Survey for England and 2011 
Census.17 This is broadly in keeping with the rate of 8.7% 
(95% CI 6.3% to 11.5%) detected in Insight 46 partici-
pants. Vitamin B12 deficiency was detected in around 5% 
of individuals aged 65–74 years old in a large UK-based 
study, compared with 3.2% (95% CI 1.9% to 5.2%) in 
Insight 46 participants.18 Another large UK-based study 
found a prevalence of 7.9% (95% CI 6.4% to 9.6%) for 
elevated TSH and 6.0% (95% CI 4.7% to 7.4%) for low 
TSH in adults over 60 years old, somewhat higher than 
the 2.6% (95% CI 1.4% to 4.4%) and 1.8% (95% CI 0.8% 
to 3.4%) detected in Insight 46 participants.19
Discrepancies in the reported prevalence of blood test 
abnormalities between Insight 46 and other studies may 
be partly related to differences in laboratory assays, thresh-
olds for defining abnormal values and participant demo-
graphics. However, it is also likely that certain blood test 
abnormalities are under-represented in Insight 46, since 
participants underwent clinical blood testing at a previous 
study visit aged 60–64 years old, and any abnormalities 
detected then were likely addressed at that time.20 Indeed, 
comparing participant results at age 60–64 with those in the 
Insight 46 study revealed that only 2 out of 9 participants 
still had anaemia, 8 out of 27 still had an elevated TSH, and 
5 out of 10 still had a low TSH.
strengths and weaknesses
A major strength of the Insight 46 study is that it involved 
a large number of participants who underwent brain 
imaging and blood testing, at an almost identical age, and 
received feedback regarding incidental findings according 
to a prespecified standardised protocol. These participants 
were all recruited from the NSHD, the longest running 
British birth cohort, which has remained broadly represen-
tative of the population born in mainland Britain in 1946.21 
Distance from London was not found to be predictive of 
participation.22
High-resolution MRI sequences were obtained using 
the same 3 Tesla PET/MRI scanner for all participants, 
and images were systematically reviewed by one of two 
experienced consultant neuroradiologists. The process 
of reviewing scans was user-friendly and automated where 
possible, allowing scans to be reported within a short time-
frame, thereby reducing the workload of the neuroradiolo-
gists. Scans were sometimes flagged for review, despite not 
having a reportable finding according to the study protocol, 
usually because the radiologist felt that the abnormality 
was serious enough to warrant further discussion. This was 
encouraged in order to avoid overlooking findings that 
might be considered actionable in the appropriate clinical 
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context. In practice, however, this did not alter the number 
of findings reported to participants.
The duty of care protocol was developed in accordance 
with the MRC and Wellcome Trust framework on manage-
ment of health-related research findings.2 Any potentially 
serious brain MRI findings or blood test abnormalities were 
reported back to participants and their GPs, in keeping 
with the ethical principle of beneficence. Findings were not 
disclosed if tests lacked clinical utility or were not actionable, 
in order to minimise participant distress and harm. Partic-
ipants were fully informed of the protocol for managing 
incidental findings as part of the consent process and were 
given the choice on whether they wanted to receive a copy 
of their blood results, thereby respecting their autonomy 
to make decisions about their own health. While it can 
be argued that research is generally not meant to benefit 
participants directly, many participants view medical input 
as an incentive to take part and there is an expectation that 
they will be informed of any serious findings. This needs to 
be balanced against the potential negative consequences of 
reporting incidental findings.5
A limitation of this study is that participant perception 
regarding the disclosure of incidental findings was not 
formally assessed, nor was the impact on their longer term 
health and psychological well-being. Many participants, 
however, gave informal feedback on post-visit evaluation 
forms that they appreciated being told about findings 
pertinent to their health and saw this as a benefit of being 
involved in the study. Moreover, almost all participants 
chose to receive a copy of their blood test results. These 
observations are consistent with the results of a study 
commissioned by the Wellcome Trust and MRC, which 
found overwhelming public support for the disclosure of 
incidental findings in research, particularly in relation to 
serious and treatable conditions.23 This is also supported by 
the work of several other studies.3 5 24 25
A further limitation of Insight 46 is that NSHD participants 
are all white Caucasian and, due to changing population 
demographics, results may not be directly generalisable to 
the current British population aged 70, or indeed younger 
populations. Furthermore, in separate analyses of recruit-
ment to Insight 46, NSHD participants with higher educa-
tional attainment, non-manual socioeconomic position and 
better self-rated health were more likely to take part.22
Implications and future work
The findings of this study will be relevant to future studies 
involving older adults, including clinical trials of secondary 
prevention drugs for Alzheimer’s disease, which often 
involve MRI-based outcome measures and blood moni-
toring. Awareness of the expected prevalence of incidental 
findings on brain MRI and clinical blood tests in this age 
group, based on predefined protocols for their determi-
nation, should allow researchers to be better prepared for 
managing them and participants to be better informed of 
their likelihood as part of the consent process.
The findings also have implications for clinical practice. 
In patients with benign-sounding headaches and normal 
neurological examination, for example, the chances of 
finding a serious intracranial cause on brain imaging is less 
than 1%.26 27 Nonetheless, patients presenting with chronic 
headache frequently undergo brain imaging, usually to 
provide reassurance, and often at the patient’s own request. 
These patients are rarely consented for the risk of discov-
ering an incidental finding, despite the potential negative 
consequences. Greater awareness of the expected frequency 
and nature of incidental findings on brain imaging and 
blood tests should allow clinicians to counsel patients 
regarding their probability, and to balance this risk against 
the potential benefits of undergoing a test when deciding 
whether it is appropriate.
While the focus of this study was on potentially serious 
brain imaging findings, awareness of the prevalence of 
other incidental abnormalities, such as white matter disease, 
would also be useful from a clinical perspective. In separate 
analyses, the distribution of white matter disease burden in 
Insight 46 participants was found to be highly non-linear, 
making it difficult to define a threshold of abnormality.28 
Ongoing work investigating these changes, including longi-
tudinal follow-up to assess their consequences, should 
help inform clinicians regarding their significance and 
management.
Further work is also needed to assess the implications 
of disclosing incidental findings in research studies, 
including the psychological effects and longer term clin-
ical consequences, as well as the impact on research integ-
rity, particularly in longitudinal population studies where 
disclosure might lead to a biased sample. Outcome data 
regarding incidental brain MRI findings in Insight 46 were 
obtained, but this does not represent final diagnoses for all 
participants, nor does it include assessment of emotional 
impact. Due to the longitudinal nature of this study, it will 
be possible to collect these outcomes in a more systematic 
way after a longer interval. This will be helpful to inform 
debates on the ethics of feeding back incidental findings to 
participants, adding to the work of several other ongoing 
studies.3–5 11 24 25
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